Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge
- 26 March 2022
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 24 (7) , 943-950
Abstract
Purpose of Review Fluoropyrimidine (FDP) chemotherapy regimens used in the treatment of solid tumors such as breast, gastrointestinal, and hepatobiliary malignancies have led to significant survival benefits. However, FDP cardiotoxicity can lead to premature termination of FDP-based chemotherapy treatments. Resuming these crucial therapies after initial FDP cardiotoxicity can be challenging for patients and healthcare providers. Recent Findings Symptomatic cardiotoxicity occurs in up to 35% of patients treated with FDP-based chemotherapy. The most common symptom is chest pain, but palpitations, dyspnea, myocardial infarction, cardiogenic shock, and cardiac arrest can also occur. Several large studies have attempted to discern clinical and genetic risk factors in those who develop FDP cardiotoxicity. With cardiac risk factor optimization and aggressive pre-treatment with anti-anginal agents, rechallenging with FDP is possible and allows patients to resume optimal cancer-directed treatment. Summary FDP cardiotoxicity remains a poorly understood identity. We highlight several recent publications attempting to define the risk factors associated with developing FDP cardiotoxicity. The management of FDP cardiotoxicity and consideration of rechallenge of FDP-based regimens highlights the importance of a multidisciplinary partnership between oncologists and cardiologists/cardio-oncologists.Keywords
Funding Information
- Division of Cancer Epidemiology and Genetics (OYFC2282)
This publication has 48 references indexed in Scilit:
- A Case of Severe Coronary Spasm Associated with 5-Fluorouracil ChemotherapyThe Korean Journal of Internal Medicine, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781Journal of Clinical Oncology, 2008
- Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast CancerJournal of Clinical Oncology, 2007
- Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective studyJournal of Cancer Research and Clinical Oncology, 2007
- Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinomaCancer, 2004
- A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinomaCancer, 2003
- CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancerEuropean Journal of Cancer, 1999